# Metaclipse Therapeutics

Source: https://onco.cc/companies/metaclipse-therapeutics/  
OnCo record `metaclipse-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Metaclipse Therapeutics makes a personalised cancer vaccine from tiny pieces of the patient's own tumour, coated with immune-boosting proteins. Its first trial tests the vaccine, alone or with an immunotherapy drug, in head and neck cancer that has come back.

## Summary

Metaclipse Therapeutics Corporation develops membrane-anchored biological adjuvants: immunostimulatory proteins linked directly to a particulate antigen source. Its lead platform, Membrex, is an autologous immunotherapy made from membrane vesicles prepared from the patient's own tumour tissue and modified with immunostimulatory proteins, given by intradermal injection; a second platform, VaxRex, applies the same adjuvants to virus-like particles for infectious disease vaccines. The company has been funded largely by grants, including SBIR awards from the NCI, a $6 million Cancer Prevention and Research Institute of Texas (CPRIT) product development award in November 2024 for Membrex with a checkpoint inhibitor in recurrent head and neck cancer, and a $355,000 NCI SBIR contract in September 2025 for work in nasopharyngeal carcinoma. Its first registered cancer trial, NCT07898124, a phase 1 study in Houston of the tumour membrane vesicle (TMV) vaccine alone or with the anti-PD-1 antibody toripalimab-tpzi around salvage surgery for loco-regionally recurrent head and neck squamous cell carcinoma, was posted on ClinicalTrials.gov in October 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Metaclipse Therapeutics Corporation
- HQ: Houston, TX
- Type: biotech
- Website: https://metaclipse.com/

## Notes

- The company website gives no street address. Houston is inferred from its JLABS @ TMC residency (from 2015), its 2025 Texas Medical Center Innovation accelerator place, its CPRIT award and the Houston trial site; its earlier news is centred on Atlanta, Georgia and a partnership with Emory's Winship Cancer Institute. Treat the headquarters city as unconfirmed.
- Founding year not stated on the company website; its news archive starts in 2012.
- OnCo has no technology record for autologous tumour membrane vesicle vaccines, so none is linked.
- The planned triple-negative breast cancer trial was not found on ClinicalTrials.gov in this scan.
- Company website read on 29 October 2026.

## Sources

- Official website: https://metaclipse.com/
- Company news archive: https://metaclipse.com/news/
- ClinicalTrials.gov: phase 1 trial of TMV vaccine with or without toripalimab in recurrent head and neck cancer (NCT07898124): https://clinicaltrials.gov/study/NCT07898124

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- targets: [PD-1](https://onco.cc/targets/pd1/)

---
JSON: https://onco.cc/api/v1/entities/metaclipse-therapeutics.json